Darunavir/cobicistat monotherapy. Experience in a tertiary hospital

Ritonavir-boosted protease inhibitor (IP/r) monotherapy: darunavir/ritonavir (DRV/r) or lopinavir/ritonavir (LPV/r) monotherapy is only provided in the major treatment guidelines in pretreated patients to prevent toxicity associated with nucleoside/nucleotide reverse transcriptase inhibitor (NRTI),...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Revista española de quimioterapia 2016-12, Vol.29 (6), p.308
Hauptverfasser:	Yunquera-Romero, L, Asensi-Díez, R, Del Rio-Valencia, J C, Muñoz-Castillo, I, Castaño-Carracedo, M A
Format:	Artikel
Sprache:	spa
Schlagworte:	Adult Cobicistat - adverse effects Cobicistat - therapeutic use Darunavir - adverse effects Darunavir - therapeutic use Drug Combinations Female HIV Infections - drug therapy HIV Infections - virology HIV Protease Inhibitors - adverse effects HIV Protease Inhibitors - therapeutic use Humans Lopinavir - therapeutic use Male Prospective Studies Ritonavir - therapeutic use Tertiary Care Centers Treatment Outcome Viral Load
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Ritonavir-boosted protease inhibitor (IP/r) monotherapy: darunavir/ritonavir (DRV/r) or lopinavir/ritonavir (LPV/r) monotherapy is only provided in the major treatment guidelines in pretreated patients to prevent toxicity associated with nucleoside/nucleotide reverse transcriptase inhibitor (NRTI), reduce costs and simplify antiretroviral treatment. To start IP/r monotherapy, according to GESIDA guidelines 2016, patients need to meet the following criteria: absence of chronic hepatitis B, plasma viral load
ISSN:	1988-9518